Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Retina > Research reveals genetic links to AMD severity and key high-risk characteristics
  • Retina

Research reveals genetic links to AMD severity and key high-risk characteristics

Kelsey Moroz

Genetic risk factors play a significant role in predicting the severity of age-related macular degeneration (AMD) and its high-risk features, according to a study.

The study included 4016 participants aged >50 of European descent. The researchers analyzed genetic risk scores (GRS) and pathway-specific subscores derived from a large genome-wide association study on AMD. These subscores were categorized based on gene-pathways related to complement, extracellular matrix (ECM) remodeling, and lipid metabolism. Logistic and multinomial regression methods were used to evaluate associations with AMD stages and features such as reticular pseudodrusen (RPD) and large drusen area (LDA).

Findings revealed that a higher GRS correlated with more severe AMD stages and specific high-risk features. The overall GRS was linked to both RPD and LDA. Complement and ECM subscores were associated with RPD, but only the complement subscore showed a significant relationship with LDA.

Reference
Garzone D, Imtiaz MA, Mauschitz MM, et al. Age-Related Macular Degeneration and Its Genetic Risk: A Population-based Study. Curr Eye Res. 2024;1-5. doi: 10.1080/02713683.2024.2388692. Epub ahead of print. PMID: 39155542.

Share

Related Content

  • Retina

Heidelberg receives FDA clearance for updated SPECTRALIS software

  • Retina

Aflibercept 8 mg demonstrates favorable safety profile in large nAMD cohort

  • Retina

Aflibercept 8 mg shows modest benefits in difficult-to-treat nAMD cases

  • Retina

AXPAXLI meets superiority endpoint in SOL-1 Phase 3 wet AMD trial

  • Diabetic Macular Edema

Hawaiian Eye Meeting update: TKI therapy may reduce treatment burden in DME and wet AMD

  • Retina

Metformin linked to lower incidence of intermediate AMD in patients with diabetes

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon